Biglycan-treated tumour cells showed significant increases in NF-κB activity, whereas this induction was attenuated by pretreatment with TLR2 and/or TLR4 inhibitors (Fig. 3I), suggesting that biglycan-induced tumour cell migration was mediated by NF-κB activation through TLRs. The gene discussed is BGN; the disease is neoplasm.